Detection of prostate-specific antigen forms and other kallikreins in prostate cancer;Détection des différentes formes du prostate-specific antigen et autres kallicréines dans le cancer de la prostate

Medecine Nucleaire

Volumn 32, Issue 1, 2008, Pages 24-30

  Jolivet Reynaud, Colette ^a   Michel, Sandrine ^a   Ott, Catherine ^a  

^a BIOMÉRIEUX   (France)

Author keywords

Diagnosis; Kallikreins; Prostate cancer; PSA; Tumor markers

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN; KALLIKREIN 11; KALLIKREIN 14; KALLIKREIN 15; KALLIKREIN 2; KALLIKREIN 3; KALLIKREIN 4; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER GROWTH; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; NONHUMAN; PREDICTION; PROGNOSIS; PROSTATE CANCER; PROTEIN DETERMINATION; SHORT SURVEY;

EID: 38749151887     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mednuc.2007.10.008     Document Type: Short Survey

References (52)

1. Hessels D., Gunnewiek J.M., Karthaus H.F., van Leenders G.J., Kiemeney L.A., Witjes J.A., et al. DD3 (PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8-15
2. van Gils M., Cornel E., Hessels D., Peelen W., Witjes J., Mulders P., et al. Molecular PCA3 diagnostics on prostatic fluid. Prostate 67 (2007) 881-887
3. Magee J.A., Araki T., Patil S., Ehrig T., True L., Humphrey P.A., et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61 (2001) 5692-5696
4. Rubin M.A., Mucci N.R., Figurski J., Fecko A., Pienta K.J., and Day M.L. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum Pathol 32 (2001) 690-697
5. Borgono C., Michael I., and Diamandis E. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2 (2004) 257-280
6. Yousef G., Obiezu C.V., Luo L., Magklara A., Borgono C., Kishi T., et al. Human tissue kallikreins: from gene structure to function and clinical applications. Adv Clin Chem 39 (2005) 11-79
7. Paliouras M., and Diamandis E. The kallikrein world: an update on the human tissue kallikreins. Biol Chem 387 (2006) 643-652
8. Stamey T.A., Yang N., Hay A.R., McNeal J.E., Freiha F.S., and Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987) 909-916
9. Daskivitch T.J., Regan M.M., and Oh W.K. Distinct prognostic of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. Urology 70 (2007) 527-531
10. Luderer A.A., Chen Y.T., Soriano T.F., Kramp W.J., Carlson G., Cuny C., et al. Measurement of the proportion of free to total-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen. Urology 46 (1995) 187-194
11. Woodrum D.L., Brawer M.K., Partin A.W., Catalona W.J., and Southwick P.C. Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 159 (1998) 5-12
12. Stephan C., Jung K., Lein M., Sinha P., Schnorr D., and Loening S. Molecular forms of Prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. Cancer Epidemiol Biomarkers Prev 9 (2000) 1133-1147
13. Shariat S.F., Abdel-Aziz K.F., Roehrborn C.G., and Lotan Y. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostactectomy with total PSA levels below 10 ng/ml. Eur Urol 49 (2006) 293-302
14. Chen Z., Chen H., and Stamey T.A. Prostate specific antigen in benign prostatic hyperplasia: purification and characterization. J Urol 157 (1997) 2166-2170
15. Wu J.T., and Liu G. Advantages of replacing the total PSA assay with the assay for PSA α1- antichymotrypsin complex for the screening and management of prostate cancer. J Clin Lab Anal 12 (1998) 32-40
16. Allard W., Zhou Z., and Yeung K. Novel immunoassay for the measurement of complexed prostate-specific antigen. Clin Chem 44 (1998) 1216-1223
17. Tabarès G., Jung K., Reiche J., Stephan C., Lein M., Peracaula R., et al. Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples. Clin Biochem 10 (2007) 343-350
18. Mikolaczyk S.D., Millar L.S., Wang T.J., et al. "BPSA", a specific molecular form of free prostate-specific antign, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55 (2000) 41-45
19. Lindon H.J., Marks L.S., Millar L.S., Knott C.L., Rittenhouse H.G., and Mikolacjzyk S.D. Benign prostate-specific antigen (BPSA) is increased in benign prostate disease. Clin Chem 49 (2003) 253-359
20. Nurmikko P., Pettersson K., Piironen T., Hugosson J., and Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 47 (2001) 1415-1423
21. Steuber T., Nurmikko P., Haese A., Pettersson K., Graefen M., Hammerer P., et al. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J Urol 168 (2002) 1917-1922
22. Michel S., Deleage G., Charrier J.P., Passagot J., Battail-Poirot N., Sibaï G., et al. Anti-free prostate specific antigen monoclonal antibody epitopes defined by mimotopes and molecular modeling. Clin Chem 45 (1999) 638-650
23. Michel S., Collomb-Clerc E., Geourjon C., Charrier J.P., Passagot J., Courty Y., et al. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies. J Mol Recognit 18 (2005) 225-235
24. Menez R, Michel S, Muller B, Bossu M, Ducancel F, Jolivet-Reynaud C, Stura E. Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl-intermediate and an activating antibody. J Biol Mol 2007, sous presse.
25. Charrier JP, Jolivet-Reynaud C, Michel S. Anticorps reconnaissant spécifiquement le PSA inactif et leurs applications diagnostiques. 2001; PCT WO 01/77180 A1.
26. Mikolajczyk S., Marker K.M., Millar L.S., Kumar A., Saedi M., Payne J., et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61 (2001) 6953-6963
27. Catalona W., Barsch G., Rittenhouse H., Evans C., Linton H., Horninger W., et al. Serum pro-prostate antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/mL prostate specific antigen. J Urol 171 (2004) 2239-2244
28. Parwani A., Marlow C., Demarzo A., Mikolajczyk S., Rittenhouse H., Veltri R., et al. Immunohistochemical staining of precursor forms of prostate-specific antigen (proPSA) in metastatic prostate cancer. Am J Surg Pathol 30 (2006) 12311236
29. Lein M., Semjonow A., Graefen M., Kwiatkowski M., Abramjuk C., Stephan C., et al. A multicenter clinical trial on the use of (-5,-7) pro prostate-specific antigen. J Urol 174 (2005) 2150-2153
30. Stephan C., Meyer H.-A., Kwiatkowski M., Recker F., Camman H., Loening s, et al. A (-5,-7) ProPSA based artificial network to detect prostate cancer. Eur Urol 50 (2006) 1014-1020
31. Peyromaure M., Fulla Y., Debré B., and Dinh-Xuan A. ProPSA: a 'pro cancer' form of PSA?. Med Hypotheses 64 (2005) 92-95
32. Fukuda M. Possible roles of tumor-associated carbohydrate antigens. Cancer Res 56 (1996) 2237-2244
33. Okada T., Sato Y., Kobayashi N., Sumida K., and Satomura S. Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid. Biochim Biophys Acta 1525 (2001) 149-160
34. Peracaula R., Tabarès G., Royle L., Harvey D., Dwek R., Rudd P., et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 13 (2003) 457-470
35. Ohyama C., Hosono M., Nitta K., Oh-eda M., Yoshikawa K., Habuchi T., et al. Carbohydrate structure and differential binding of prostate-specific antigen to Maackia amurensis lectin between prostate cancer and benign hypertrophy. Glycobiology 14 (2004) 671-679
36. Deperthes D., Frenette G., Brillard-Bourdet M., Bourgeois L., Gauthier F., Tremblay R., et al. Potential involvement of kallikrein hK2 in the hydrolysis of the human seminal vesicle proteins after ejaculation. J Androl 17 (1996) 659-665
37. Denmeade S.R., Lövgren J., Khan S.R., Lilja H., and Isaacs J.T. Activation of latent protease function of pro-hK2 but not proPSA, involves autoprocessing. Prostate 48 (2001) 122-126
38. Takayama T., Fujikawa K., and Davie E.W. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and human glandular kallikrein. J Biol Chem 34 (1997) 21582-21588
39. Haese A., Graefen M., Becker C., Noldus J., Katz J., Cagiannos I., et al. The role of human kallikrein 2 for prediction of pathiological organ confined prostate cancer. Prostate 54 (2003) 181-186
40. Steuber T., Niemela P., Haese A., Pettersson K., Erbersdobler A., Felix Chun K.H., et al. Association of free prostate-specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate 63 (2005) 13-18
41. Steuber T., Vickers A., Haese A., Becker C., Pettersson K., Felix Chun K.H., et al. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed to human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int J Cancer 118 (2006) 1234-1240
42. Steuber T., Vickers A., Serio A., Väisänen V., Haese A., Pettersson K., et al. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 53 (2007) 230-240
43. Gao J., Collard R.L., Bui L., Herington A.C., Nicol D.L., and Clements J.A. Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastastic prostate cancer. Prostate 67 (2007) 348-360
44. Diamandis E., Okui A., Mitsui S., Luo L., Soosaipillai A., Grass L., et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 62 (2002) 295-300
45. Nakamura T., Scorilas A., Stephan C., et al. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 63 (2003) 6543-6546
46. Ochiai A., Shukla A., Davis J., Fritsche H., and Bhadkamkar V. Is there a role for serum tissue kallikrein in detection of prostate cancer?. Urology 70 (2007) 519-522
47. Yousef G., Stephan C., Scorilas A., Ellatif M., Jung K., Kristiansen G., et al. Differential expression of the kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 56 (2003) 287-292
48. Stephan C., Yousef G., Scorilas A., Jung K., Jung M., Kristiansen G., et al. Diamandis E. Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J Urol 169 (2003) 361-364
49. Borgono C.A., Grass L., Soosaipillai A., Yousef G.M., Petraki C., Howarth D., et al. Human kallikrein 14: a new biomarker for ovarian and breast cancer. Cancer Res 63 (2003) 9032-9041
50. Shaw J., Grass L., Sotiropoulou G., and Diamandis E. Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. Clin Biochem 40 (2007) 104-110
51. Lilja H., Ulmert D., Becker C., serio A., Nilson J.-A., Abrahamson P.-A., et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at 44 to 50 years. J Clin Oncol 25 (2007) 431-435
52. Mikolajczyk S., Song Y., Wong J., Matson R., and Rittenhouse H. Are multiple markers the future of prostate cancer diagnostics?. Clin Biochem 37 (2004) 519-528